Tag Archive for: #CellTherapy #CGT

Hot Topic: Will in vivo breathe new life into CGT?

It’s now almost nine years since the first CAR-T therapies, Kymriah and Yescarta, were approved by the FDA. These therapies and others have revolutionised the treatment of certain hard-to-treat blood cancers, such as ALL and some B-cell lymphomas. There was rightly huge elation at the time. CAR-Ts were a real breakthrough, offering a lifeline – […]

Leucid Bio to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference

London, UK – 28 August 2025 – Leucid Bio (“Leucid” or the “Company”), a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies using the Company’s proprietary lateral CAR platform, today announced that it will attend the Morgan Stanley 23rd Annual Global Healthcare Conference in New York. Filippo Petti, Chief Executive […]

© Optimum Strategic Communications.